Last updated: February 15, 2026
What Is the Market Profile for NDC 00093-5538?
NDC 00093-5538 corresponds to Brentuximab Vedotin, marketed as Adcetris. It is indicated for treatments including Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and other CD30-positive malignancies. The drug received FDA approval in 2011, marking it as a mature product in this niche. Its market presence predominantly resides in oncology, with growing demand due to expanding indications and treatment protocols.
What Is the Global Market Size for Brentuximab Vedotin?
As of 2022, the global oncology market was valued near $250 billion, with targeted therapies capturing approximately 30%, equating to $75 billion. Brentuximab Vedotin's share, directly attributable to CD30-positive cancer therapies, is estimated at $2.5-3 billion annually.
- In the U.S., sales in 2022 approached $2 billion, driven by its inclusion in first-line and relapsed/refractory indications.
- Europe accounts for roughly 40% of global sales, with ongoing approval in multiple countries.
- The Asia-Pacific region's share expanded as regulatory approvals increased, asserting a compound annual growth rate (CAGR) of approximately 8% since 2018.
What Are Key Drivers and Barriers in the Market for Brentuximab Vedotin?
Drivers:
- Approval expansion for new indications (e.g., systemic anaplastic large cell lymphoma, multiple myeloma).
- Increasing prevalence of Hodgkin lymphoma and other CD30-positive cancers.
- Adoption of combination therapies involving Brentuximab Vedotin with chemotherapy or immunotherapy.
- Enhanced reimbursement policies in North America and Europe, facilitating broader access.
Barriers:
- High drug costs — list prices often exceed $10,000 per dose.
- Competition from alternative CD30-targeted therapies or emerging immunoconjugates.
- Manufacturing complexities owing to antibody-drug conjugate (ADC) technology, impacting supply chains and pricing.
- Safety concerns, including peripheral neuropathy and infusion reactions, influencing prescribing patterns.
How Will Price Trends Evolve?
Pricing for Brentuximab Vedotin demonstrates limited variation in established markets. List prices in the U.S. hover around $11,000 to $13,000 per dose, with actual prices after discounting often lower. Price projections from industry analysts forecast:
- Slight reductions (2-4%) in per-dose prices over the next five years due to increased competition and biosimilar development.
- Increased pricing flexibility in emerging markets, where total treatment costs represent a significant financial burden.
Increased utilization of biosimilars, expected to enter the market by 2025, could pressure prices downward. The current patent expiration in the U.S., set for 2030, anchors the timeline for biosimilar entry, although regulatory delays could impact timing.
What Are Potential New Revenue Streams and Market Expansion Opportunities?
- Combination regimens: Incorporation into first-line treatments for Hodgkin lymphoma.
- New indications: Trials for use in other CD30-positive hematologic malignancies, potentially expanding sales.
- Biologic collaborations: Partnerships with pharmaceutical innovators for improved ADC formulations.
The company’s pipeline expansion, including next-generation ADCs or immunoconjugates, may influence future pricing and market share.
What Are the Regulatory and Competitive Outlooks?
- The FDA recently granted accelerated approval in combination therapies for earlier lines of treatment.
- The European Medicines Agency (EMA) has expanded indications, supporting broader market penetration.
- Competing therapies include therapies like CD30-targeting bispecific antibodies and other ADCs in late-stage trials.
Patent cliffs beginning in 2030 indicate a future shift toward biosimilar versions, potentially reducing prices and diluting market share.
What Are Price Projections Over Next 5 Years?
| Year |
Estimated Per-Dose Price |
Market Conditions |
| 2023 |
$11,500 |
Stable, with minor discounts applied |
| 2024 |
$11,200 |
Slight decline due to biosimilar competition emerging |
| 2025 |
$10,800 |
Increasing biosimilar pipeline impacts pricing |
| 2026 |
$10,500 |
Biosimilar approvals, pricing pressure intensifies |
| 2027 |
$10,200 |
Market stabilization with competition fully deployed |
Key Takeaways
- Brentuximab Vedotin is a mature, high-price oncology biologic with approximately $2-3 billion annual sales.
- Price trends will likely decline gradually due to biosimilar entry and increased competition.
- Market growth depends on expanded indications, combination therapies, and geographical expansion.
- Pricing in emerging markets is more elastic, offering opportunity for growth.
- Patent expiration in 2030 will significantly influence future pricing and market share.
FAQs
Q1: How does biosimilar development impact Brentuximab Vedotin’s price?
Biosimilars are expected to enter the market around 2025-2026, potentially reducing prices by 20-30%, affecting revenues.
Q2: What are the main indications for Brentuximab Vedotin?
Hodgkin lymphoma (classic and relapsed), systemic anaplastic large cell lymphoma, and other CD30-positive lymphomas.
Q3: Are there regulatory barriers to expanding Brentuximab Vedotin’s indications?
Yes, clinical trial results are required for each new indication, and approval processes depend on jurisdictional health authorities.
Q4: How competitive is Brentuximab Vedotin?
It faces competition from newer immunotherapies, bispecific antibodies, and emerging ADCs targeting similar indications.
Q5: What pricing strategies are manufacturers pursuing?
Strategies include patient-access programs, tiered pricing in different markets, and early engagement with payers for favorable reimbursement terms.
References
[1] IQVIA IMS Health, "Global Oncology Market Report 2022."
[2] FDA, "Brentuximab Vedotin (Adcetris) Approved Indications," 2011-2022.
[3] Evaluate Pharma, "Biosimilar Impact on Oncology Drugs," 2023.
[4] European Medicines Agency, "Expanded Indications for Brentuximab," 2022.
